论文部分内容阅读
（目的）检测50例肺癌中C－erbH-2癌基因蛋白、ras癌基因蛋白p21、增殖细胞核抗原（PCNA）。（方法）用免疫用化SP法。（结果）C－erbB-2、p21、PCNA在50例肺癌中的阳性表达分别为34．00％、4400％、94.00％。在低分化肿瘤、高TNM分期肿瘤及有淋巴结和远隔转移的病例中C－erbB－2、p21显著升高（P＜0.05和P＜0．01）。PCNA指数随肿瘤分级升高而升高，并与组织学类型相关。〔结论）C－erb-2、p21、PCNA高表达与肺癌进展和预后有关，可作为判断肺癌预后的生物学指标并指导临床治疗。
(Objective) To detect C-erbH-2 oncogene protein, ras oncogene protein p21, and proliferating cell nuclear antigen (PCNA) in 50 cases of lung cancer. (Method) Immunosuppressed SP method. (Results) The positive expression of C-erbB-2, p21, and PCNA in 50 cases of lung cancer were 34.00%, 4400%, and 94.00%, respectively. In patients with poorly differentiated tumors, high TNM stage tumors, and cases with lymph nodes and distant metastases, C-erbB-2 and p21 levels were significantly increased (P<0.05 and P<0.01). The PCNA index increased with increasing tumor grade and correlated with histological type. [Conclusion] The high expression of C-erb-2, p21 and PCNA is associated with the progression and prognosis of lung cancer. It can be used as a biological index to judge the prognosis of lung cancer and guide clinical treatment.